ERBB2 and renal pelvis/ureter urothelial carcinoma: Similarly, a recent real-world retrospective study demonstrated that adjuvant therapy with disitamab vedotin and toripalimab in patients with HER2-overexpressing UTUC resulted in a 12-month DFS rate of 91.7%, compared to 62.5% in those without adjuvant treatment.